March 14, 2022
Bayer said on March 11 that it has filed its oral androgen receptor inhibitor Nubeqa (darolutamide) for an additional indication of prostate cancer with distant metastasis in Japan. In Japan, the drug was approved in January 2020 for the treatment...read more